Viewing Study NCT03797261

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:41 PM
Ignite Modification Date: 2026-02-26 @ 12:20 AM
Study NCT ID: NCT03797261
Status: TERMINATED
Last Update Posted: 2021-12-07
First Post: 2019-01-07
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
Sponsor: AbbVie
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia View
None Non-Hodgkin's Lymphoma View
None Diffuse Large B-cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Acute Myeloid Leukemia View
None Non-Hodgkin's Lymphoma View
None Cancer View
None Venetoclax View
None AMG 176 View
None diffuse large B-cell lymphoma (DLBCL) View